Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with <sup>90</sup>Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI

<div>Cross-sectional imaging studies of a 53 y/o male with NET of pancreatic origin with hepatic metastases treated with two cyles of PRRT (195 mCi and 170 mCi of <sup>90</sup>Y/<sup>111</sup>In -DOTATOC). The patient responded well to the first therapy with SPECT/CT images (a, b) showing a markedly decreasing uptake ratio after the 2<sup>nd</sup> therapy as compared with the 1<sup>st</sup> treatment cycle. Correspondingly, the size of the lesions as documented by the <i>b</i> = 700 s/mm<sup>2</sup> diffusion-weighted MR images (c, e, g) showed an important decrease in size 10 weeks after treatment. In the ADC maps (d, f, h), an increase is seen already at T<sub>2</sub>, 48 h after initiation of therapy as an early sign of treatment response.</div>

Contrast Media & Molecular Imaging

fig4

Figure 4

Figure 4: Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with <sup>90</sup>Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI 

Figure 4 | Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI 